EZH2 Cooperates with BRD4-NUT to Drive NUT Carcinoma Growth by Silencing Key Tumor Suppressor Genes

Yeying Huang; R. Taylor Durall; Nhi M. Luong; Hans J. Hertzler; Julianna Huang; Prafulla C. Gokhale; Brittaney A. Leeper; Nicole S. Persky; David E. Root; Praju Vikas Anekal; Paula Montero Llopis; Clément N. David; Jeffery L. Kutok; Alejandra Raimondi; Karan Saluja; Jia Luo; Cynthia A. Zahnow; Biniam Adane; Kimberly Stegmaier; Catherine E. Hawkins; Christopher Ponne; Quan Le; Geoffrey I. Shapiro; Madeleine E. Lemieux; Kyle P. Eagen; Christopher A. French

doi:10.1158/0008-5472.can-23-1475

Abstract

Repression of tumor suppressor genes, including CDKN2A, by EZH2 provides a mechanistic rationale for combining EZH2 and BET inhibitors for the clinical treatment of NUT carcinoma. See related commentary by Kazansky and Kentsis, p. 3827.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Huang et al. (2023) studied this question.

synapsesocial.com/papers/69d97995a1d151c65f684476 https://doi.org/10.1158/0008-5472.can-23-1475

View Full Paper

Ask AI

Bookmark

Share

EZH2 Cooperates with BRD4-NUT to Drive NUT Carcinoma Growth by Silencing Key Tumor Suppressor Genes

Abstract

Discussion

Cite This Study

EZH2 Cooperates with BRD4-NUT to Drive NUT Carcinoma Growth by Silencing Key Tumor Suppressor Genes

Abstract

Discussion

Cite This Study

Keep reading

Keep reading